Lyon, may 30, 2017 – 18h CET – Adocia (Euronext Paris : FR0011184241 – ADOC), a biopharmaceutical company specializing in the treatment of diabetes through innovative formulations of proteins approved, today announced that six abstracts validating the application of its proprietary technology BioChaperone® for the development of innovative treatments for diabetes have been accepted for poster presentation at the occasion of the 77èmes Scientific Sessions of the American Diabetes Association®, which will take place from 9 to 13 June 2017 at San Diego (California, Usa).
Boost your gains
“We are delighted to present a solid and varied backgrounds of our programs to 77èmes Scientific Sessions of the ADA, which meet every year, world leaders committed to improving the lives of people living with diabetes. This gives us the opportunity to highlight the significant progress made by the company, in particular in respect of BioChaperone Lispro, our program ready to enter Phase 3. ” commented Gérard Soula, ceo of Adocia. “We are also pleased to share the promising data from two of our programs in the early phase, BioChaperone Glucagon, and combinations, made possible by BioChaperone, glargine and agonists of receptors to GLP-1. ”
Below you will find detailed information about the six abstracts accepted for programs that use the technology BioChaperone®:
Poster n°964: Ultra-rapid BioChaperone Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14 – Day Treatment
Study in Subjects with Type 1 Diabetes mellitus (T1DM)
Speaker : Dr. Tim Heise, MD
Session : Clinical Therapeutics/New Technology-Insulins
Date and time :Saturday, June 10 from 11:30 to 12:30 PDT
Place : Hall B
The results of this study will also be discussed during a poster session moderated by moderators, titled “Insulins with a Twist” on Sunday, 11 June 2017 12:00 to 13:00 pm PDT in Hall B. During this session, the moderators will share their vision of recent advances in the development of insulin therapy.
Post # 994: Ultra-rapid BioChaperone Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 2 Diabetes mellitus (T2DM)
Speaker : Dr. Tim Heise, MD
Session : Clinical Therapeutics/New Technology-Insulins
Date and time :Saturday, June 10 from 11:30 to 12:30 PDT
Place : Hall B
Poster n°996: Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone Lispro (BCLIS) in Healthy Japanese Subjects
Speaker : Dr. Gregory Meiffren, PhD
Session : Clinical Therapeutics/New Technology-Insulins
Date and time :Saturday, June 10 from 11:30 to 12:30 PDT
Place : Hall B
Poster n°1150: Preclinical efficacy of a stable aqueous formulation of human glucagon with BioChaperone technology (BC GLU)
Speaker : Dr. Gregory Meiffren, PhD
Session: Clinical Therapeutics/New Technology-Insulins
Date and time :Saturday, June 10 from 11:30 to 12:30 PDT
Place : Hall B
Poster n°1153: BioChaperone technology enables rhGlucagon aqueous formulation for use in rescue and dual-hormone artificial pancreas (DHAP)
Speaker : Dr. Olivier Soula, PhD, MBA
Session: Clinical Therapeutics/New Technology-Insulins
Date and time :Saturday, June 10 from 11:30 to 12:30 PDT
Place : Hall B
Poster n°1029: BioChaperone technology enables the development of glargine-liraglutide and glargine-dulaglutide combinations
Speaker : Dr. Rémi Soula, PhD, MBA
Session: Clinical Therapeutics/New Technology-Insulins
Date and time :Saturday, June 10 from 11:30 to 12:30 PDT
Place : Hall B
About scientific sessions of the ADA
The Scientific Sessions of the American Diabetes Association provide to researchers and health professionals around the world the exclusive opportunity to exchange ideas and acquire knowledge on the recent progress of research on diabetes, as well as on its treatment and its management. Attendees will discover more than 3000 presentations of original research, take part in invigorating discussions with the best experts in the field and expand their professional network.
About ADOCIA
Adocia is a biotechnology company clinical stage specialized in the development of innovative formulations of proteins already approved. The portfolio of injectable products of Adocia for the treatment of diabetes, which includes four products in clinical phase and six products in the preclinical phase, is one of the widest and most differentiated in the industry.
The platform’s proprietary technology BioChaperone® aims to improve the effectiveness and/or safety of therapeutic proteins and facilitate their use by patients. Adocia customizes BioChaperone to each protein for a given application, in order to address needs specific to patients.
The clinical pipeline of Adocia includes four innovative formulations of insulin for the treatment of diabetes: two formulations, ultra-fast insulin analog (BioChaperone Lispro U100 and U200), a formulation of rapid-acting insulin human (HinsBet U100), and a combination of slow insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of glucagon, human (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1 (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with hormones prandial synergistic (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide) and a concentrated formulation is fast-acting insulin human (HinsBet U500), all in preclinical development.
Adocia aims to deliver “innovative medicines for everyone, everywhere.”
To learn more about Adocia, please visit us on www.adocia.com
Boost your gains